Intravenous acellular human amniotic fluid prevents ischemic cardiac remodeling

Area of Science:

• Cardiovascular Research
• Regenerative Medicine
• Immunology

Background:

• Amniotic products are known for their immunomodulatory and tissue repair capabilities.
• Cardiac remodeling after injury contributes to heart failure.
• Investigating novel therapeutic agents for cardioprotection is crucial.

Purpose of the Study:

• To evaluate the impact of acellular human amniotic fluid (hAF) on cardiac remodeling post-myocardial infarction.
• To explore the cellular mechanisms underlying hAF's cardioprotective effects.

Main Methods:

• Acellular hAF was prepared from donated amniotic fluid.
• hAF was administered intravenously to rats following coronary ligation (myocardial infarction model).
• In vitro studies assessed H9C2 cell response to hypoxic stress with and without hAF.

Main Results:

• hAF treatment led to a nearly sixfold reduction in infarct size and fibrosis in rats.
• hAF-treated H9C2 cells exhibited improved viability and mitochondrial stability under hypoxia.
• Apoptosis was significantly reduced in hAF-exposed cells during hypoxic conditions.

Conclusions:

• A single dose of acellular hAF provides significant functional cardioprotection in a rat model of cardiac injury.
• The cardioprotective mechanism involves enhanced cellular tolerance to hypoxic stress, mediated by proteins within hAF.
• Acellular hAF presents a promising, readily available adjunct therapy for cardioprotection.